Research
Daraxonrasib and chemotherapy shrink tumors in pancreatic cancer trial
In an early-stage trial of 61 patients with metastatic pancreatic cancer, tumors shrank or disappeared in 60.7% who received daraxonrasib with chemotherapy.

An early-stage trial found that daraxonrasib combined with gemcitabine and nab-paclitaxel shrank or eliminated tumors in patients with metastatic pancreatic cancer who had not yet received treatment for that advanced disease. Of 61 patients, 60.7% had tumors shrink or disappear, including 8.2% whose tumors were no longer detectable on scans. Tumor growth stopped in 90.2% of patients, according to the results presented at the EORTC-NCI-AACR Symposium.
The median time before tumors returned or began growing again was 12.8 months. At 12 months, 76.6% of patients were alive. The reports describe the findings as promising but say they need careful interpretation because the early-phase trial had no group receiving chemotherapy alone. A larger, randomized phase 3 trial, RASolute-303, is comparing daraxonrasib alone and with chemotherapy against chemotherapy alone.
Reporting on this story
- Fox News New drug combo shrinks tumors in most patients facing aggressive cancer type (opens in a new tab)
- MedPage Today 'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment (opens in a new tab)
- The Guardian Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ (opens in a new tab)
- Medical Xpress Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy (opens in a new tab)


